While all pediatric gastroenterologists know that the title of this blog entry is right, it is helpful to have data.
A recent study (Clin Gastroenterol Hepatol 2012; 10: 612-19) used a reflux questionnaire to evaluate responsiveness of regurgitation from 2 randomized controlled trials. The trials compared a newer acid blocker (AZD0865 dosed at 25-75 mg/day)) to esomeprazole (20-40 mg/day). Patients had either non-erosive reflux disease (NERD , n=1460), or reflux esophagitis, (RE, n=1314). Inclusion criteria included the presence of substernal burning for ≥4 days/week.
Regurgitation-taste (RT), defined as an “acid taste in the mouth,” or regurgitation-movement (RM), defined as an “unpleasant movement of material upwards from the stomach” were analyzed. Among NERD patients, either or both symptoms were present in 53% at baseline compared with 54% among the RE group. In both NERD and RE patients, the presence of these regurgitation symptoms was associated with a poorer response to therapy.
- Complete response of NERD patients with regurgitation symptoms: RT 34%, RM 26%; in comparison to heartburn response of NERD patients which was 49%
- Complete response of RE patients with regurgitation symptoms: RT 44%, RM 33%; in comparison to heartburn response of NERD patients which was 55%
Additional references/blog entries: